Video

Multiple Myeloma: New Therapies and Changing Cytogenetics

Publish date: January 6, 2012

 

SAN DIEGO – Dr. Kenneth C. Anderson, associate editor of The Oncology Report, discusses new therapies for multiple myeloma and changing risk factors in presentations at the 2011 annual meeting of the American Society of Hematology (ASH).

Recommended Reading

Chemotherapy Alone Bests Radiation for Nonbulky Hodgkin's Lymphoma
MDedge Hematology and Oncology
Obinutuzumab Equals Rituximab in Relapsed Indolent NHL
MDedge Hematology and Oncology
Most Lymphomatoid Papulosis Has Benign Course
MDedge Hematology and Oncology
Mantle Cell Lymphoma: BTK Inhibitor Scores Again
MDedge Hematology and Oncology
Return ED Visits by Sickle Cell Patients Common
MDedge Hematology and Oncology
Second-Cancer Signal Affirmed After Lenalidomide for Myeloma
MDedge Hematology and Oncology
Pediatric Hodgkin's Regimens Suit Adolescents and Young Adults
MDedge Hematology and Oncology
'Best Results' Yet for Poor-Prognosis Elderly With DLBCL
MDedge Hematology and Oncology
Evidence Mounts for Early Treatment of Smoldering Myeloma
MDedge Hematology and Oncology
Brentuximab vedotin ushers in a new era in treating lymphomas
MDedge Hematology and Oncology